Health care costs for treatment of disseminated breast cancerDAHLBERG, L; LUNDKVIST, J; LINDMAN, H et al.European journal of cancer (1990). 2009, Vol 45, Num 11, pp 1987-1991, issn 0959-8049, 5 p.Article

Cognitive TheoryRESTLE, F; SHIFFRIN, R. M; CASTELLAN, N. J et al.sd, 319 p.Book

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patientsSANDSTRÖM, M; LINDMAN, H; NYGREN, P et al.Journal of clinical oncology. 2005, Vol 23, Num 3, pp 413-421, issn 0732-183X, 9 p.Article

Early response of breast cancer bone metastases to chemotherapy evaluated with MR imagingCIRAY, I; LINDMAN, H; ASTRÖM, K. G. O et al.Acta radiologica (1987). 2001, Vol 42, Num 2, pp 198-206, issn 0284-1851Article

Can axillary dissection be avoided by improved molecular biological diagnosis?LINDAHL, T; ENGEL, G; AHLGREN, J et al.Acta oncologica (Stockholm). 2000, Vol 39, Num 3, pp 319-326, issn 0284-186XConference Paper

FEC mobilized stem cells for high-dose therapy in breast cancer patientsLINDMAN, H; WIKLUND, T; HOLTE, H et al.Acta oncologica (Stockholm). 1999, Vol 38, Num 2, pp 239-245, issn 0284-186XArticle

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trialROSELL, J; NORDENSKJÖLD, B; BENGTSSON, N.-O et al.British journal of cancer. 2011, Vol 104, Num 6, pp 899-902, issn 0007-0920, 4 p.Article

High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancerLJUNGMAN, P; BJÖRKSTRAND, B; VILLMAN, K et al.Bone marrow transplantation (Basingstoke). 1998, Vol 22, Num 5, pp 445-448, issn 0268-3369Article

Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyWILKING, N; LIDBRINK, E; WIST, E et al.Annals of oncology. 2007, Vol 18, Num 4, pp 694-700, issn 0923-7534, 7 p.Article